- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
European Nurses Boost Biosimilar Education With Newly Translated Guide to Switching
The European Specialist Nurses Organisation has launched 7 new translations of its guide to the management of switches between reference biologics and biosimilars.
The European Specialist Nurses Organisation (ESNO) has launched 7 new translations of its guide to the management of switches between reference biologics and biosimilars. In addition to the original version in English, the guide is now available in German, French, Spanish, Polish, Italian, Portuguese, and Dutch.
The translations of the guide are available to be downloaded at ESNO’s website and are also made available in hard copy by the ESNO office.
Ber Oomen, executive director at ESNO, said in a statement announcing the translations, “Nurses play a very important role in guiding a patient through their treatment path. Our aim with the guide was to empower the nurse in their interactions with their patients. By translating the guide in to 7 additional languages, we aim to educate even more of the nursing community by providing the information in their language.”
The guide, which was originally launched last year, addresses the specific role of the specialized nurse in interacting with patients during the switching process.
The guide is built on existing European Commission guidelines for the healthcare community, and it emphasizes the nurse’s key link between the prescriber and patient and role in treatment adherence.
The included in the guide are definitions of biologic and biosimilar medicines, information about switching and substitution, information on the benefits of using biosimilars, information on the nurse’s role in managing the switch, pharmacovigilance guidance, case studies, real-world evidence, and flow charts that describe how the switch, follow-up, and support processes will unfold for patients.
The ENSO has previously indicated that the guide will eventually be translated into 23 EU languages.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
No Differences in Long-Term Drug Survival Between Biosimilar, Originator TNF Inhibitors
August 15th 2024An analysis of subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases found no significant differences in survival or discontinuation rates due to inefficacy or adverse events, with biosimilars showing lower overall discontinuation rates and higher retention rates.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Indian Providers Boast Interchangeability for Insulin Biosimilars Despite Debates in the US
August 5th 2024The introduction of biosimilar insulins, particularly insulin glargine, is crucial for improving insulin accessibility and adherence among patients with diabetes in India, according to a study evaluating expert opinions from Indian doctors.
